Clinical trial Recruiting at 1 site Interventional Ages 40 to 70

Radial Shock Wave Therapy for knee bone marrow edema in people with knee OA

Official title: Effectiveness of Extracorporeal Shock Wave Therapy on Periarticular Bone Marrow Edema in Patients With Knee Osteoarthritis: A Randomized Double-Blind Sham-Controlled Trial

Run by Dokuz Eylul University · NCT07887893 · Data updated 2026-11-12

A noninvasive shock wave therapy is tested to see if it helps people aged 40–70 with knee osteoarthritis and bone marrow edema.

More Knee Arthritis, Osteoarthritis trials

Quick facts

Study typeInterventional
Ages40 Years to 70 Years
SexAll
Enrollment24 (estimated)
SponsorDokuz Eylul University
Academic / other
Locations1 site (Izmir, Balcova)
StatusRecruiting
StartedMarch 26, 2026
Main results expectedNovember 1, 2026
Study endsDecember 1, 2026
Registry record updatedOctober 22, 2026
Trial IDNCT07887893 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 40–70 with knee OA (KL 2–3) and MRI-confirmed unilateral BME in the knee.

Probably not a fit

Patients without BME or with confounding knee conditions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares radial extracorporeal shock wave therapy (ESWT) to sham ESWT in adults with knee OA and MRI-confirmed bone marrow edema around the knee. Participants have Kellgren–Lawrence grade 2–3 OA, unilateral BME in a knee compartment, and meet safety criteria. The treatment aims to improve pain and function by improving blood flow and promoting bone remodeling, without invasive procedures. Outcomes are assessed using symptom questionnaires and imaging as appropriate. Recruitment is centered at Dokuz Eylul University in Izmir, Turkey.

Why it matters

Potential benefit: If successful, patients may experience reduced knee pain and improved function without surgery or injections.

How similar studies have gone: Previous research has explored ESWT for musculoskeletal conditions; this study applies ESWT to knee BME with OA, an area with limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 40-70 years
* Radiographic evidence of knee osteoarthritis classified as Kellgren-Lawrence grade 2 or 3
* Unilateral BME in the bones around the knee, limited to either the medial or lateral compartment of the knee joint, as confirmed by MRI. The affected sites may include the medial femoral condyle, medial tibial plateau, or both; or the lateral femoral condyle, lateral tibial plateau, or both
* Willingness to participate in the study
* Provision of written informed consent

Exclusion Criteria:

* Insufficient cognitive ability to complete the questionnaires
* Physical therapy, corticosteroid injection, or surgery involving the affected area within the previous 6 months
* Previous ESWT treatment
* Open wounds, infection, bleeding, skin lesions, or metal implants around the knee
* Presence of a cardiac pacemaker
* Peripheral arterial occlusive disease
* Polyneuropathy or sensory impairment
* Inflammatory rheumatic disease
* Severe cardiovascular disease
* Pregnancy
* History of epilepsy
* History of malignancy
* Bleeding disorders

Where it's running

  • Dokuz Eylul University
    Izmir, Balcova, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.